KLK4 and prostate carcinoma: Successful in planta production was also extended to an engineered SFTI-1 variant (SFTI-FCQR) that inhibits human kallikrein-related peptidase 4, a target for prostate cancer treatment (Supplementary Fig. S10E) (Swedberg et al., 2009).